BioCentury
ARTICLE | Clinical News

Loxo gains on Phase I RET inhibitor data

May 17, 2018 2:37 PM UTC

Loxo Oncology Inc. (NASDAQ:LOXO) gained $28.03 (20%) to $167.53 Thursday after reporting response data from a Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In 32 evaluable patients with RET fusion-positive tumors, oral LOXO-292 led to an overall response rate (ORR) of 69%, including an ORR of 65% in 26 non-small cell lung cancer (NSCLC) patients and 83% in six papillary thyroid cancer patients. Additionally, 84% of patients had radiographic tumor reductions of 19-67%...